HC Wainwright reissued their buy rating on shares of Viracta Therapeutics (NASDAQ:VIRX – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.
Viracta Therapeutics Trading Down 2.9 %
Shares of NASDAQ:VIRX opened at $0.91 on Tuesday. Viracta Therapeutics has a 12 month low of $0.43 and a 12 month high of $2.38. The company has a 50-day moving average price of $0.91 and a 200 day moving average price of $0.70. The company has a market cap of $35.70 million, a price-to-earnings ratio of -0.69 and a beta of 0.93.
Viracta Therapeutics (NASDAQ:VIRX – Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). As a group, equities analysts forecast that Viracta Therapeutics will post -1.28 EPS for the current year.
Institutional Inflows and Outflows
About Viracta Therapeutics
Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.
Featured Stories
- Five stocks we like better than Viracta Therapeutics
- Overbought Stocks Explained: Should You Trade Them?
- Comprehensive PepsiCo Stock Analysis
- Pros And Cons Of Monthly Dividend Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.